sermorelin and Hypopituitarism

sermorelin has been researched along with Hypopituitarism* in 2 studies

Other Studies

2 other study(ies) available for sermorelin and Hypopituitarism

Article	Year
[Diagnostic use of the GRF test in the study of GH secretion]. Anales espanoles de pediatria, 1987, Volume: 27, Issue:4 A good response after an intravenous bolus of GRF-1-29 NH2 in patients with hypopituitary dwarfism localities the site of the GH-deficiency in the hypothalamus (GRF deficiency). These patients could be treated with GH and GRF. Never the less some patients with hypothalamic responses after TRH don't respond after GRF. Probably these non responders need GRF in pulsatile or prolonged administration and T4 substitution before and during the test if TSH is also deficient. At least some cases without GRF response can be accepted as pure pituitary only GH would be effective. Topics: Adolescent; Adult; Child; Child, Preschool; Diagnosis, Differential; Dwarfism, Pituitary; Female; Gonadotropin-Releasing Hormone; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hypopituitarism; Hypothalamic Diseases; Hypothalamo-Hypophyseal System; Male; Peptide Fragments; Secretory Rate; Sermorelin; Thyrotropin-Releasing Hormone	1987
The use of growth hormone-releasing hormone in the diagnosis and treatment of short stature. Hormone research, 1985, Volume: 22, Issue:1-2 We have assessed the role of growth hormone-releasing hormone (GHRH) as a diagnostic test in 40 children and young adults with growth hormone deficiency (GHD), principally using the GHRH(1-29)NH2 analogue. Following 200 micrograms GHRH as an acute intravenous bolus, serum GH rose to normal or just subnormal levels in 13 out of 17 children with structural lesions, and in 8 of 14 patients with idiopathic GHD or panhypopituitarism. Of 9 children (mean age 12 years) with GHD following treatment with cranial irradiation for nonendocrine tumours, all responded acutely to GHRH. 12- and 24-hour infusions with GHRH(1-29)NH2, and 1- and 2-week treatments with twice-daily subcutaneous GHRH(1-29)NH2, showed persistent stimulation of GH release. It is concluded that many children with GHD of diverse aetiology will respond both acutely and chronically to treatment with GHRH. Topics: Adolescent; Adult; Body Height; Brain Neoplasms; Child; Child, Preschool; Growth Disorders; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hypopituitarism; Insulin-Like Growth Factor I; Peptide Fragments; Sermorelin; Somatomedins	1985

Article

Year

[Diagnostic use of the GRF test in the study of GH secretion].

Anales espanoles de pediatria, 1987, Volume: 27, Issue:4

A good response after an intravenous bolus of GRF-1-29 NH2 in patients with hypopituitary dwarfism localities the site of the GH-deficiency in the hypothalamus (GRF deficiency). These patients could be treated with GH and GRF. Never the less some patients with hypothalamic responses after TRH don't respond after GRF. Probably these non responders need GRF in pulsatile or prolonged administration and T4 substitution before and during the test if TSH is also deficient. At least some cases without GRF response can be accepted as pure pituitary only GH would be effective.

Topics: Adolescent; Adult; Child; Child, Preschool; Diagnosis, Differential; Dwarfism, Pituitary; Female; Gonadotropin-Releasing Hormone; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hypopituitarism; Hypothalamic Diseases; Hypothalamo-Hypophyseal System; Male; Peptide Fragments; Secretory Rate; Sermorelin; Thyrotropin-Releasing Hormone

1987

The use of growth hormone-releasing hormone in the diagnosis and treatment of short stature.

Hormone research, 1985, Volume: 22, Issue:1-2

We have assessed the role of growth hormone-releasing hormone (GHRH) as a diagnostic test in 40 children and young adults with growth hormone deficiency (GHD), principally using the GHRH(1-29)NH2 analogue. Following 200 micrograms GHRH as an acute intravenous bolus, serum GH rose to normal or just subnormal levels in 13 out of 17 children with structural lesions, and in 8 of 14 patients with idiopathic GHD or panhypopituitarism. Of 9 children (mean age 12 years) with GHD following treatment with cranial irradiation for nonendocrine tumours, all responded acutely to GHRH. 12- and 24-hour infusions with GHRH(1-29)NH2, and 1- and 2-week treatments with twice-daily subcutaneous GHRH(1-29)NH2, showed persistent stimulation of GH release. It is concluded that many children with GHD of diverse aetiology will respond both acutely and chronically to treatment with GHRH.

Topics: Adolescent; Adult; Body Height; Brain Neoplasms; Child; Child, Preschool; Growth Disorders; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hypopituitarism; Insulin-Like Growth Factor I; Peptide Fragments; Sermorelin; Somatomedins

1985